Ferritin levels throughout childhood and metabolic syndrome in adolescent stage

M.F. Suárez-Ortegón [a,b,*], E. Blanco [c], S. McLachlan [a], J.M. Fernandez-Real [d], R. Burrows [e], S.H. Wild [a], B. Lozoff [f], S. Gahagan [c]

[a] Basic and Clinic Sciences Group-Department of Basic Sciences of Health, Pontificia Universidad Javeriana, Cali, Colombia
[b] Nutrition Group, Universidad del Valle, Cali, Colombia
[c] Division of Child Development and Community Health, University of California, San Diego, La Jolla, CA, USA
[d] Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain
[e] University of Chile, Santiago, Chile
[f] Center for Human Growth and Development, University of Michigan, Ann Arbor, MI, USA

Abstract *Background and aim:* Increased ferritin levels have been widely associated with cardiovascular risk in adults. Whether ferritin levels and their changes during childhood are related to metabolic syndrome (MetS) at adolescence is unknown. We aimed to evaluate these associations using levels of ferritin at 5, 10 and 16 years and their linear increases and patterns of sustained increased levels across childhood.

Methods and results: There were four samples evaluated according to non-missing values for study variables at each stage (5 years: 562; 10 years: 381; and 16 years: 567 children; non-missing values at any stage: 379). MetS risk was evaluated as a continuous Z score. Patterns of sustained increased ferritin (highest tertile) and slope of the change of ferritin per year across the follow-up were calculated. Ferritin levels in the highest versus lowest tertile at five and 16 years were significantly positively associated with MetS risk Z score at adolescence in boys and these associations were unaffected by adjustment for covariates. Having high, compared to low/moderate ferritin level at 2 or more time periods between 5 and 16 years was related to higher Mets Z-score in boys only [e.g. 5—10 years adjusted-beta (95 %CI):0.26 (0.05—0.48),P < 0.05]. In girls, ferritin Z score at 10 and 16 years was positively and independently associated with HOMA-IR Z score. In girls, the slope of ferritin per year in the highest tertile was positively associated with MetS risk Z-score [adjusted-beta (95 %CI):0.21 (0.05—0.38),P < 0.05].

Conclusions: Ferritin levels throughout childhood are positively related to cardiometabolic risk in adolescence, with associations varying by sex.

© 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

* Corresponding author. Department of Basic Sciences of Health, Pontificia Universidad Javeriana, Calle 18 No.118 - 250 Cali, Colombia 2º piso Edificio Raúl Posada, Cali, Colombia.
E-mail address: fabian.suarezuv@gmail.com (M.F. Suárez-Ortegón).

Introduction

Increased iron stores, defined by ferritin levels, have been associated with metabolic syndrome [1] and risk of diabetes in general adult populations in many studies [2,3]. Iron is an active cofactor of oxidative biological reactions whose products have deleterious effects on insulin sensitivity and endothelial function [4]. Interestingly, not only iron overload but also iron deficiency is related to worsening of metabolic profile through mechanisms still unclear [5,6].

To date, little is understood about whether the iron-cardiometabolic risk link exists in early life. Children have a lower capacity for iron storage than adults since this physiological function becomes fully developed in adulthood. It is unknown if changes in ferritin levels across infancy and adolescence are associated with metabolic syndrome, and if these changes could have an additive effect on cardiometabolic risk. Whether increased ferritin levels, low ferritin levels or both are involved in higher cardiometabolic risk during childhood is also unknown. Therefore, we conducted a study to evaluate longitudinal and cross-sectional associations between ferritin levels measured at 5, 10 and 16 years with metabolic syndrome and its components at 16−17 years in a cohort of Chilean children. In addition, we evaluated if a linear increase and sustained patterns of increased ferritin across childhood were related to MetS risk in adolescence.

Methods

Subjects

The cohort included Chilean infants of low/middle socioeconomic status from urban Santiago recruited between 1991 and 1996 for a trial of iron supplementation. The infants, recruited at 4 months, were healthy, full-term singleton infants weighing 3 kg or more at birth. At 6 months, those who did not have iron deficiency anaemia were randomized to receive iron supplementation or usual nutrition between 6 and 12 months. The cohort was assessed for developmental outcomes, including ferritin levels, in infancy and at 5, 10 and 16 years [7]. At 16−17 years, participants were also assessed for obesity and cardiovascular risk [8]. Three samples from the cohort were evaluated: 1) participants with no missing values for ferritin and covariates at 5 years and for cardiometabolic risk outcomes at 16 years (n = 565); 2) participants with no missing values for ferritin and covariates at 10 years and for cardiometabolic risk outcomes at 16 years (n = 381); 3) participants with no missing values for ferritin, covariates and cardiometabolic risk outcomes at 16 years (n = 567). A sample with no missing values for the study variables at any stage of the follow-up was also evaluated (n = 379). The study was approved by the institutional review boards of the University of Michigan, the Institute of Nutrition and Food Technology (University of Chile),

and the University of California, San Diego. Participants and their primary caregiver provided informed and written consent.

Methods for clinical measurements of blood pressure, body mass index and waist circumference and biochemical markers of fasting glucose, triglycerides, and HDL cholesterol has been described previously [7,8].

Metabolic syndrome and insulin resistance

It was decided to evaluate a continuous MetS score instead of using some paediatric MetS definitions. The use of the latter approach had supposed lower statistical power on the basis of few cases meeting categorical criteria from MetS definitions (e.g high glucose as glucose > 100 mg/dL). Similarly, there is no consensus about cut-off values in the different components of MetS in children and adolescents. A continuous variable of Z score or scale of SD units for MetS was created from an average of Z scores of blood pressure, glucose, triglycerides, HDL cholesterol and waist circumference [9]. Distribution of these MetS components was normalised if required, before calculating the Z scores. The Z scores of diastolic and systolic blood pressures were averaged to get a single Z score for blood pressure, and the HDL-C Z score was multiplied by −1 before obtaining the overall MetS score, to ensure that all of the components of MetS had the same positive association with regard to cardiometabolic risk. Insulin resistance was estimated by using the formula of the homeostatic model assessment (HOMA-IR) as: (glucose [mg/dL] x insulin [mU/mL])/405 [10]. We estimated proportions of non-overweight, overweight and obesity using both the CDC and WHO reference populations. Cut-points used were <1 BMI z score for non-overweight, ≥ 1 BMI Z score and <2 Z BMI z score overweight, and ≥ 2 BMI z score for obesity.

Data analysis

The analyses were conducted in female and male subjects separately given differences by sex in cardiometabolic outcomes. Study variables were described as median (and interquartile range) and proportions, and differences were estimated by Mann−Whitney U test and Chi Square test, respectively. Wilcoxon and sign tests were used to detect significant differences or changes in values of ferritin across the different time points during the follow-up.

We defined two kinds of variable of change over time for ferritin levels as exposure variable. One was on the basis of ferritin levels defined in tertiles at 5, 10 and 16 years for participants with data available at those time points. Patterns of ferritin levels were then identified from different combinations of high ferritin (highest tertile) and low/moderate ferritin (lowest and middle tertile). The second approach was the calculation of the slope of ferritin concentration per year and use this parameter as continuous and categorical variable (tertiles). The slope provides information on variation of ferritin concentration by each unit of time, in this case years (11 years of follow-up), which were extrapolated from the trend line of the three

time points: 5, 10 and 16 years. Multiple linear regression was used to evaluate associations of ferritin tertiles (with lowest tertile as reference) at each stage of follow up and patterns and slope of ferritin across the follow-up with the variation of MetS Z score. For the patterns of repeated ferritin measurements, low/moderate ferritin at two stages of an interval or in all of the stages of follow-up was used as reference. We calculated sex-specific z-scores for ferritin in our cohort at each age (5, 10, and 16 years) and used them to model associations between ferritin at each age and Z scores or SD units of MetS components and insulin resistance using linear regression. The adjustment consisted of covariates at the respective stage (5, 10, and 16−17 years): age, BMI Z score, Tanner stage, and haemoglobin levels. At adolescent stage (16−17 years) C reactive protein (CRP) levels were also available and cross-sectional associations were furtherly adjusted for this inflammatory marker. Associations between patterns of repeated ferritin measurements and cardiometabolic risk variables in adolescence were adjusted for covariates at the end of a determined interval (e.g. if ferritin pattern during the interval 5−10 years, covariates used were those at 10 years). We also adjusted this kind of associations by using baseline values of covariates along with changes of

these across the interval (if ferritin pattern during the interval 5−10 years, for instance BMI Z score at 5 years and also its change between 5 and 10 years were covariates).

To approximate to normal distribution ferritin, SBP, DBP and CRP values were log-transformed in girls and boys, WC and TG in girls and HDL-C in boys. In boys WC was transformed as $(1/square)*-1$, TG as $(1/square\ root)*-1$, and HDL-C as its logarithm.

All analyses were performed using stata 14.0.

Results

The study variables are described by sex and age at follow-up in Table 1. No differences by sex were found at 5 years of age for ferritin, haemoglobin, and BMI Z score. At 10 years of age, girls had higher sexual development than boys (Table 1). At the adolescent stage, boys had higher levels of ferritin, haemoglobin, systolic and diastolic blood pressure, glucose compared to girls, and girls had higher sexual development, HDL-C and insulin levels compared to boys. In boys there was a significant increase in ferritin levels showed in Table 1 from 5 to 10 years and from 10 to 16−17 years (Wilcoxon and Sign tests $P < 0.05$). In girls,

Table 1 Description of study population.

At 16−17 years	Girls	Boys	P value
	n = 270	n = 297	
Age (years)			**0.024**
Ferritin (μg/L)	19.1 (11.7−28.2)	32.7 (22.7−7.1)	**<0.0001**
Haemoglobin (g/dL)	13.7 (13−14.3)	15.9 (15−16.6)	**<0.0001**
CRP (mg/L)	0.45 (0.15−1.35)	0.38 (0.12−1.20)	0.2849
BMI Z score	0.67 (0.03−1.26)	0.42 (−0.22 to 0.42)	0.0813
Tanner stage			
2	−	0.6	
3	5.9	16.4	
4	53.3	56.9	**<0.0001**
5	40.7	25.9	
Waist circumference (cm)	79.6 (72.5−88.3)	78.4 (73.5−86.4)	0.7939
SBP (mmHg)	108 (100−113.5)	115 (108−122)	**<0.0001**
DBP (mmHg)	68 (61−71)	70 (65−75)	**<0.0001**
Glucose (mg/dL)	86.1 (80.9−92.1)	90.7 (84.4−96.7)	**<0.0001**
TG (mg/dL)	74.9 (57.9)	73.7 (56.1−102.2)	0.9309
HDL-C (mg/dL)	41.5 (35.1−49.5)	36.6 (30.8−42.2)	**<0.0001**
Insulin (ulU/ml)	7.1 (5.1−10.3)	6.2 (4.3−9.7)	**0.0399**
HOMA-IR	1.48 (1.05−2.15)	1.40 (0.96−2.17)	0.3315
MetS score*	−0.01 (−0.36 to 0.33)	−0.07 (−0.38 to 0.38)	
At 5 years	n = 268	n = 297	
Ferritin (μg/L)	22.3 (15.3−32.3)	21.3 (14.3−29.1)	0.0954
Haemoglobin (g/dL)	12.9 (12.5−13.4)	12.9 (12.4−13.5)	0.9584
BMI Z score	0.87 (0.23−1.57)	0.83 (0.18−1.55)	0.8449
At 10 years	n = 183	n = 198	
Ferritin (μg/L)	27.4 (21.1−36.8)	25.6 (19.8−34.9)	0.5094
Haemoglobin (g/dL)	136 (130−141)	137 (131−142)	0.4204
BMI Z score	0.87 (0.01−1.42)	0.94 (0.26−1.56)	0.0900
Tanner stage			
1	39.3	70.7	
2	43.1	29.2	**<0.0001**
3	16.9	−	
4	0.5	−	

*Difference by sex does not apply since MetS Z scores were calculated as sex specific.

changes in ferritin levels were also significant, but with increase from 5 to 10 years, and decrease from 10 to 16−17 years (Wilcoxon and Sign tests P < 0.05). The slope for average annual change in ferritin across the follow-up was higher in boys than girls [mean (SD) 0.67 ± 1.82 v. −0.50 (1.38), P < 0.001]. Specific slopes of change in ferritin levels between 5 and 10 years were [mean (SD)] 0.89 ± 3.23 and 0.99 ± 2.55 in boys and girls respectively. Between 10 and 16−17 years the slope for boys was 0.49 ± 3.01 and for girls −1.68 ± 2.31.

With regard to overweight and obesity, this Chilean cohort presented a considerable proportion of both conditions (∼44% at 5 and 10 years, and 34% at 16−17 years) (Supplementary Table 1). Serum ferritin levels increased across categories of non-overweight, overweight, and obesity in each age group analysed (Supplementary Table 2).

Table 2 shows linear regression analyses for relationships between sex-specific Z score of ferritin at the three ages and sex-specific Z scores for MetS components and insulin resistance at adolescent stage. In girls, Z scores for ferritin levels at 10 and 16−17 years of age were significantly (P = 0.046 and P = 0.014) and independently associated with the Z score of insulin resistance but not with any of the MetS components at the adolescent stage. In boys, ferritin level Z score at 5 years old was inversely associated with the Z score of HDL-C in adolescence in unadjusted and adjusted models, whereas significant unadjusted associations with Z scores of waist circumference, HDL-C and insulin resistance did not remain significant after adjustment for covariates. In adolescence, there were significant cross-sectional associations between Z scores of ferritin and fasting glucose and triglycerides independent of adjustment for covariates in boys and with insulin resistance (measured by HOMA-IR) in both sexes.

Ferritin levels in the highest tertile at five years (compared to the lowest tertile) were positively associated with MetS risk Z score in adolescence in boys (Fig. 1), and this association was unaffected by adjustment for baseline BMI Z score and haemoglobin levels. Also in boys, there was a significant cross-sectional association between ferritin levels measured in adolescence in the highest tertile and increasing MetS risk Z score, independently of adjustment for BMI Z score, CRP levels, haemoglobin levels and Tanner stage. No significant associations were found between ferritin at 10 years and MetS Z score at adolescent stage. No significant associations were found in girls (Fig. 1).

Having high, compared to low/moderate ferritin level at 2 or more time periods between 5 and 16 years was related to higher Mets risk z-score in boys only (p < 0.05) (Fig. 2). A sensitivity analysis by adjusting the associations in Fig. 2 for baseline values of covariates along with changes of these across the interval, showed very similar beta coefficients to those in Fig. 2 (Supplementary Table 3).

The slope values for ferritin levels as a continuous variable were marginally associated (P = 0.06) with MetS risk z-score only in girls and significantly associated with MetS risk z-score when comparing highest to lowest tertile of ferritin slope (Supplementary Table 4). High ferritin levels at the three time points was associated with MetS rik Z score in boys only (Supplementary Table 5). More details on these associations are provided in the supplementary material as "additional results" along with a sensitivity analysis and an extra-adjustment.

In the different age stages, the correlation between ferritin and MetS Z scores was stronger in overweight (including obese) children in comparison with non-overweight children (Supplementary Figs. 1, 2 and 3).

Discussion

This study showed that ferritin levels in infancy and childhood are positively and longitudinally associated with cardiometabolic risk at adolescent stage. Moreover, patterns of sustained high levels of ferritin throughout childhood were associated with worse metabolic profile in adolescence. In general, in male but not in female subjects the associations of ferritin at different ages with MetS were independent of covariates. However, only in girls, a linear increase in terms of the slope of ferritin from measurements at 5, 10 and 16 years, was independently associated with MetS risk. The above findings highlight serum ferritin as a factor associated with cardiometabolic risk from early life and indicate sex differences in the association.

Contrast with previous studies

Only five studies conducted to date on the association of ferritin and other iron status markers with cardiometabolic risk variables in children were identified from a systematic literature search performed in September 2016. All studies are cross-sectional and four are from Asian paediatric populations (Table 3). All these studies included children and/or adolescents from general populations, except the study by Bougle and Brouard in Canadian children, who studied overweight and obese children specifically [11]. This latter study is the only one, along with the present studies, reporting associations adjusted for inflammatory markers. Lee et al., like our study, evaluated outcomes of MetS and its components [12], while the others evaluated MetS components (categorical or continuous variables). In general, the studies showed no significant association between ferritin and most of the cardiometabolic risk outcomes they evaluated. Zhu et al. did not find association between ferritin and any MetS component in 1126 Chinese children [13]. Ferritin levels were significantly and positively associated with waist circumference in the studies by Lee et al. and Jeon et al. in Korean children [12,14], with triglycerides in the studies by Bougle and Brouard and Kim et al. [11,15], and inversely associated with HDL-C in the studies by Bougle and Brouard, Kim et al., and Lee et al. [11,12,15] None of the studies reported associations between ferritin and fasting glucose or blood pressure.

The contrasting and significant cross-sectional findings in Chilean boys with regard to the above studies

Table 2 Sex-stratified relationships of ferritin level Z scores at the three points of follow-up with Z scores of MetS-related markers and insulin resistance (as Z score) at 16–17 years by sex.

	Girls				Boys			
	Unadjusted		Adjusted		Unadjusted		Adjusted	
	Beta(95% CI)	P value	Beta(95% CI)	P value	Beta(95% CI)	P value	Beta(95% CI)	P value
At 5 years[a]								
Z SBP (mmHg)*	−0.01 (−0.13 to 0.11)	0.852	−0.01 (−0.12 to 0.10)	0.854	0.03 (−0.07 to 0.14)	0.538	0.007 (−0.09 to 0.11)	0.890
Z DBP (mmHg)*	0.006 (−0.11 to 0.13)	0.920	0.01 (−0.11 to 0.13)	0.851	0.01 (−0.09 to 0.12)	0.831	−0.009 (−0.11 to 0.10)	0.864
Z Glucose (mg/dL)	−0.03 (−0.16 to 0.087)	0.544	−0.04 (0.16−0.08)	0.503	0.07 (−0.03 to 0.18)	0.163	0.07 (−0.03 to 0.19)	0.162
Z TG (mg/dL)	−0.09 (−0.22 to 0.02)	0.131	−0.10 (−0.22 to 0.02)	0.113	0.08 (−0.02 to 0.19)	0.124	0.05 (−0.04 to 0.16)	0.285
Z HDL-C (mg/dL)	−0.08 (−0.20 to 0.04)	0.192	0.08 (−0.04 to 0.20)	0.205	**−0.24(−0.35 to 0.13)**	**<0.001**	**−0.22(−0.33 to 0.11)**	**<0.001**
Z Waist (cm)	0.03 (−0.09 to 0.16)	0.586	0.02 (−0.07 to 0.12)	0.593	**0.12(0.01 to 0.23)**	**0.022**	0.07 (−0.01 to 0.16)	0.103
Z HOMA-IR	0.03 (−0.09 to 0.15)	0.601	0.03 (−0.09 to 0.15)	0.617	**0.12(0.01 to 0.23)**	**0.030**	0.08 (−0.01 to 0.19)	0.099
At 10 years[b]								
Z SBP (mmHg)*	−0.01 (−0.15 to 0.12)	0.844	−0.03 (−0.16 to 0.09)	0.598	0.05 (−0.09 to 0.20)	0.463	0.01 (−0.11 to 0.15)	0.794
Z DBP (mmHg)*	−0.08 (−0.23 to 0.05)	0.245	−0.08 (−0.22 to 0.05)	0.211	−0.03 (−0.17 to 0.10)	0.643	−0.04 (−0.18 to 0.09)	0.548
Z Glucose (mg/dL)	−0.01 (−0.16 to 0.13)	0.846	−0.01 (−0.17 to 0.13)	0.807	0.12 (−0.02 to 0.27)	0.109	*0.13(−0.01 to 0.28)*	*0.077*
Z TG (mg/dL)	0.04 (−0.09 to 0.19)	0.537	0.03 (−0.11 to 0.17)	0.674	0.11 (−0.01 to 0.25)	0.090	0.08 (−0.04 to 0.21)	0.214
Z HDL-C (mg/dL)	−0.02 (−0.15 to 0.11)	0.732	−0.006 (−0.14 to 0.13)	0.924	**−0.16(−0.30 to 0.02)**	**0.021**	*−0.13(−0.27 to 0.006)*	*0.062*
Z Waist (cm)	0.08 (−0.06 to 0.22)	0.282	0.04 (−0.06 to 0.15)	0.432	0.08 (−0.06 to 0.22)	0.259	−0.01 (−0.11 to 0.08)	0.785
Z HOMA-IR	**0.17(0.02 to 0.31)**	**0.025**	**0.14(0.002 to 0.29)**	**0.046**	0.12 (−0.02 to 0.26)	0.094	0.85 (−0.05 to 0.22)	0.229
At 16–17 years[c]								
Z SBP (mmHg)*	0.009 (−0.10 to 0.12)	0.868	−0.05 (−0.16 to 0.05)	0.316	0.13 (−0.01 to 0.27)	0.070	0.03 (−0.10 to 0.17)	0.643
Z DBP (mmHg)*	−0.0004 (−0.11 to 0.11)	0.994	−0.06 (−0.17 to 0.05)	0.314	0.10 (−0.03 to 0.35)	0.154	0.05 (−0.09 to 0.20)	0.474
Z Glucose (mg/dL)	0.09 (−0.02 to 0.20)	0.128	0.08 (−0.04 to 0.20)	0.205	**0.15(0.009 to 0.29)**	**0.037**	**0.19(0.045 to 0.34)**	**0.010**
Z TG (mg/dL)	0.07 (−0.04 to 0.19)	0.199	0.02 (−0.93 to 0.15)	0.640	**0.27(0.12 to 0.41)**	**<0.001**	**0.16(0.03 to 0.30)**	**0.015**
Z HDL-C (mg/dL)	0.09 (−0.01 to 0.21)	0.102	*0.11(−0.003 to 0.24)*	*0.058*	0.03 (−0.11 to 0.17)	0.658	0.12 (−0.01 to 0.26)	0.078
Z Waist (cm)	**0.12 (0.008 to 0.24)**	**0.035**	0.04 (−0.02 to 0.11)	0.199	**0.23 (0.09 to 0.37)**	**<0.001**	0.01 (−0.05 to 0.08)	0.596
Z HOMA-IR	**0.18 (−0.06 to 0.29)**	**0.002**	**0.14 (0.02 to 0.25)**	**0.014**	**0.25 (0.11 to 0.40)**	**<0.001**	**0.18 (0.05 to 0.31)**	**0.004**

*Adjustment model also included height. Significant associations are shown in bold. SBP, systolic blood pressure. DBP, diastolic blood pressure. TG, triglycerides. HDL-C, HDL cholesterol. HOMA-IR, homeostatic model assessment insulin resistance. BMI, body mass index. CRP, C reactive protein.
  [a] Estimates were adjusted for BMI Z score and haemoglobin level.
  [b] Estimates were adjusted for BMI Z score, haemoglobin level and tanner stage.
  [c] Estimates were adjusted for BMI Z score, CRP level, haemoglobin level and tanner stage.

Fig. 1 Linear regression for longitudinal (A and B) and cross-sectional (C) associations between tertiles of ferritin at the three points of follow-up and the MetS Z score. A, n = 565. B = n = 381. C, n = 567. ◇ Reference. ● Unadjusted. □ Adjusted: Longitudinal associations with ferritin at 5 and 10 years were adjusted for the respective baseline BMI Z score and haemoglobin level, and tanner stages for 10 year's evaluation; Cross-sectional association at 16–17 years were adjusted for BMI Z score, CRP level, haemoglobin level and tanner stage. Means (SD) of MetS Z score by tertiles are also provided.

could be explained in terms of differences in age range and study design. In the Chilean cohort, participants were evaluated at the same age at each evaluation and cardiometabolic risk outcomes were at the adolescent stage (16–17 years), a higher and narrower age range than in the above studies.

The longitudinal and cross-sectional positive associations between ferritin at each stage of childhood (except at 10 years) and MetS described in the present study were significant in boys but not in girls. This sex difference appears to be explained by a threshold effect derived from higher levels of cardiometabolic risk factors in boys at the adolescent stage, rather than by higher iron stores in boys since at 5 years there was no significant sex difference in ferritin levels. Two recent prospective studies in adults which evaluated both sexes have also

Fig. 2 Linear regressions associations between MetS Z score at 16/17 years andpatterns of combined high(H) and low/moderate(L/M) ferritin concentration throughout the follow-up. ◇ Reference. ● Unadjusted. ☐ Adjusted: aassociations were adjusted for the values of BMI Z score and haemoglobin level and tanner stage(if applicable) at the end of the interval (e.g interval 5−10 years included covariates of BMI Z score, haemoglobin levels, and tanner stage at 10 years old). For major comparability of the intervals of follow-up, this analysis used cases with no missing values for all of the three points of measurements (n = 379 at each stage).

shown significant associations between ferritin and development of MetS with stronger associations for men than for premenopausal women [16,17], although one study in a Swiss population did not find difference by sex [18]. However, some cross-sectional studies have described non-significant ferritin-MetS associations in men [19−21]. The association could be stronger in men

given higher iron storage capacity in comparison with women.

The relationship between the pattern of repeated measurements of ferritin and MetS appeared to differ by sex. In boys, a pattern of sustained high ferritin levels throughout the follow-up was significantly associated with MetS risk, whereas in girls a linear change in ferritin levels

across follow-up was associated with MetS risk. It is of notice that the slope of change in ferritin levels in girls tended to be negative due to puberty-related menstrual iron losses. Therefore, an association between the slope of change in ferritin levels and HOMA-IR should be interpreted as the less decline in ferritin concentration across the follow-up the higher the values of the insulin resistance index. In boys the association appear markedly influenced by threshold effects of ferritin and/or cardiometabolic risk outcomes. There are no studies on trajectories of ferritin and cardiometabolic risk in adults, although one study evaluated change in ferritin regarding development of MetS after 6.5 years follow-up [22]. In this study conducted in a Finnish population, men or women who had incident MetS presented higher changes in ferritin values between baseline and the end of the follow-up [22]. Future studies should test patterns of sustained high ferritin and slopes from repeated measurements of ferritin over time regarding cardiometabolic outcomes in adults and other paediatric populations to contrast our findings by sex.

Only in girls, there was a longitudinal association between ferritin at 10 years and insulin resistance at adolescence, and later at adolescence, ferritin levels were cross-sectionally associated with the index of insulin resistance (HOMA-IR) in both sexes. This could be explained in terms of sexual development differences. At 10 years, 60% of the girls were in adolescent stage v. 29% in boys, and at 16−17 years both sexes reached adolescent stage. None of the three studies that evaluated relationship between ferritin and HOMA-IR in Table 3 found those variables significantly associated [11,12,15]. In line with our findings, Aigner et al. found in Caucasian adolescents an isolated inverse association between the soluble transferrin receptor (sTfR)/ferritin index (lower values represent higher body iron content) and HOMA-IR in girls, and consistent inverse associations with systolic and diastolic blood pressure, and triglyceride levels in boys [23]. However, in that study no associations with ferritin and sTfR were separately evaluated. The finding in Chilean girls contrasts with the lack of association between ferritin at 10 and 16 years with MetS score in the same girls, as higher insulin resistance is strongly correlated with higher MetS scores. Given that the relationship between iron and glucose/insulin metabolism is bi-directional [5], insulin levels could modulate iron stores throughout the growth process in girls. However, the difference by sex in the ferritin-MetS association must be mainly explained by menstrual blood loses in girls.

Serum ferritin levels were increased in overweight and obese children, and the correlation between serum ferritin at the different age stages and MetS Z score at adolescence was stronger in overweight children v. non-overweight children. A higher body mass implies a higher capacity for iron storage. Higher ferritin in people with obesity could also be explained by insulin resistance rather than by obesity itself [24,25]. Since ferritin is an acute phase reactant, their circulating levels might be influenced by conditions in which chronic low grade inflammation is prominent, with parallel iron retention in several tissues, as an evolutionary mechanism to avoid iron use by potential pathogens [26]. Another known source of increased serum ferritin levels is liver injury, which results in the release of ferritin into the bloodstream [27]. In this sense, hepatic steatosis, a condition characterized by lipid accumulation in the liver in terms of triglycerides and fatty acids, appears to lead to an environment of increased oxidative stress, insulin resistance and necrotic signals in obese subjects, ending up in hepatic damage [28]. In addition, adipocytes secrete inflammatory interleukins which contribute to increased inflammatory activity of obese subjects [29]. Thus, liver injury, hypertrophied adipocytes and inflammation concur during the clinical course of overweight and obesity, to alter the circulating levels of ferritin. However, despite the influence of weight status, the ferritin-MetS association found in boys remained significant after adjustment for BMI Z score.

Ethnicity is an important aspect to take into account when it comes to cardiometabolic risk. The vast majority of the Chilean population is mestizo: mixed Spanish and Indigenous ancestry. Although, Indigenous ethnicities are different according to geographic location, several studies have shown higher risk of diabetes and cardiovascular disease in Indigenous groups such as PIMA (Arizona, U.S), Australian and Canadian Aboriginal communities [30−32]. Although genetic susceptibility may be implied, as observed for the PIMA community [29], social inequalities are more likely to explain why Indigenous ethnic groups are more prone to cardiometabolic risk [31,32]. Since these groups are ethnic minorities, poverty, lower educational level and higher rates of unemployment might be associated with higher cardiometabolic risk. In addition to the partial Indigenous ancestry, the Chilean children of this cohort belong to low and middle socioeconomic status, and thus higher cardiometabolic risk is expected. However, the above aspects would support an inverse ferritin-MetS association rather than a positive association as it was found. In fact, because of poor nutrition socioeconomically deprived or marginal communities would tend to have lower iron levels concomitantly with hypercaloric diets, unfavourable environments for physical activity and higher rates of cardiovascular risk factors [33]. However, further studies in children from diverse ethnic groups are needed to confirm the longitudinal and cross-sectional associations we found.

Several limitations have to be mentioned. First, because of lack of availability of variables, there was no evaluation of cross-sectional associations between ferritin cardiometabolic risk at 5 and 10 years since cardiometabolic risk outcomes were measured only at the adolescent stage. Second, there were no available measures of subclinical/clinical inflammation at 5 and 10 years, meaning that it is not possible to account for ferritin acting as an acute phase reactant. Adjustment for BMI Z score might partly have corrected the associations for the potential effect of subclinical inflammation derived from adiposity on ferritin levels. It is also important to bear in mind that CRP levels in adolescence were not associated with cardiometabolic

Table 3 Some studies* in children on ferritin and Metabolic syndrome.

Authors, year of publication (reference)	Study	Location/Universe	Study/Year of survey	Age range (years)	Male (%)	Total sample	Cardiovascular risk markers (outcomes and analysis-effect estimate)	Ferritin: Continuous/ categorical-ordinal	Association		Adjustments
									Yes	No	
Lee et al., 2014 (12)	Cross-sectional	Korea/school- aged children	Korean Pediatric Cohort Study	7 and 10	50.5	1350	1-Metabolic syndrome (categorical) [difference in ferritin levels by having or not MetS] 2-Glucose, WC, HDL-C, SBP, DBP, HOMA-IR and TG (continuous). [Partial Pearson Correlations]	Continuous	With WC (r = 0.07) and HDL-C (r = −0.10) [p < 0.05].	With MetS. Glucose (r = −0.004) HOMA-IR (r = 0.03) TG (r = 0.03) SBP(r = 0.03) DBP(r = 0.04) [p > 0.05].	Age and sex (for MetS components) Unadjusted analysis for MetS.
Kim et al., 2016 (15)	Cross-sectional	Korea/Paediatric general population	Korean National Health and Nutrition Survey IV 2009−2010	10−18	64.1	1879	HDL-C, TG, and HOMA-IR (continuous). Sex-stratified multivariable linear regression.	Continuous	With HDL-C (inverse) in both sexes. With TG in boys only.	With HOMA-IR in both sexes.	Age, height, weight, place, smoking status, drinking, physical activity, serum 25(OH)D level, total daily energy intake, fat intake, protein intake, calcium intake, and menarche in girls
Jeon et al., 2013 (14)	Cross-sectional	Korea/Paediatric general population	Korean National Health and Nutrition Survey V 2010	10−18	54.4	849	High glucose as ≥ 100 mg/dL High TG as ≥ 100 mg/dL Low HDL-C as ≤ 40 mg/dL High blood pressure (SBP ≥ 130 or DBP ≥ 85 (mmHg)) High WC (WC ≥ 90th). [Linear regression with ferritin as outcome]	Continuous	With high WC only	With High glucose, high TG, low HDL-C, and high blood pressure (SBP ≥ 130 or DBP ≥ 85 (mmHg))	Age
Bougle and Brouard et al., 2012 (11)	Cross-sectional	France/overweight and obese children attending specialized outpatient clinic	Research on child obesity/NP	11.4 ± 3.0 years old	53	502	Glucose, SBP, DBP, HDL-C, TG, and HOMA-IR (continuous). Multivariable linear regression.	Continuous	With TG and HDL-C (inverse).	Glucose, SBP, DBP, and HOMA-IR	Age, sex, BMI Z score and fibrinogen levels.
Zhu et al., 2016 (13)	Cross-sectional	China/school- aged children	Epidemiological study in Guangzhou, China/ 2014	7−14	46.5	1126	High glucose as ≥ 5.6 mmol/L High TG as ≥ 1.7 mmol/L Low HDL-C as < 1.03 mmol/L High SBP (≥90th) High DBP (≥90th) High WC (≥90th). [Logistic regression with ferritin as independent variable]	Categorical (quartiles, and first/ lowest quartile as reference)	None of the MetS components	With all of the MetS components	Age, gender, physical activities, and dietary behaviours

This study	Cross-sectional/ Longitudinal	Chile/General paediatric population	Epidemiological study in Santiago, Chile	5, 10 and 16–17 years	52.3	567	1-Metabolic syndrome at 16–17 years (continuous) 2-Glucose, WC, HDL-C, SBP, DBP, HOMA-IR and TG at 16–17 years (continuous). Sex-stratified multivariable linear regression.	Categorical at 5, 10 and 16–17 years (tertiles, and first/lowest tertile as reference)	Girls: Association of ferritin at 10 and 16 years with HOMA-IR and MetS Boys: Association (inverse) of ferritin at 5 years with HDL-C. Cross-sectional Association of ferritin with glucose, TG, HOMA-IR and MetS	Associations with ferritin at 5 and 10 years adjusted for BMI Z score, haemoglobin level and tanner stage Associations with ferritin at 16–17 years adjusted for BMI Z score, CRP level, haemoglobin level and tanner stage

WC, waist circumference. LDL-C, LDL cholesterol. HDL-C, HDL cholesterol. TG, triglycerides. DBP, diastolic blood pressure. SBP, systolic blood pressure. FG, fasting glucose. Q, quartile. * found in PUBMED by applying the searching: iron AND (cardiometabolic risk OR cardiovascular risk OR metabolic syndrome) AND (children OR adolescents) (until May 25/2016). [in vitro studies, genetic studies and those conducted adults populations or patients with diseases were not included].

risk and insulin resistance and did not affect the associations in the multivariable models (data not shown). Third, hepatic injury increases ferritin levels and the associations reported in this study were not adjusted for hepatic injury markers. However, in general children were in good health status. Our findings in girls might need further characterisation in large samples at different tanner stages to properly evaluate puberty-related changes in iron status and cardiometabolic risk.

On the other hand, our study has some relevant strengths. To the best of our knowledge this is the first study evaluating longitudinal association between ferritin levels and cardiometabolic risk in paediatric populations. Moreover, the Chilean cohort analysis is the first study analysing patterns of three repeated measurements of ferritin over time regarding cardiometabolic risk. The study is also the first to adjust the cross-sectional ferritin-cardiometabolic risk association in children for a systemic inflammation marker such as CRP levels. The evaluation of the children at specific ages in the Chilean cohort allowed a more precise characterisation of the association in terms of a more homogeneous group of subjects in comparison with previous studies.

Conclusion

Both serum ferritin at different time points in childhood and its change or patterns of sustained high concentration throughout childhood are associated with MetS and insulin resistance but with differences by sex in those relationships. Patterns of sustained high ferritin and slopes from repeated measurements of ferritin over time should be tested regarding cardiometabolic outcomes in adults and other paediatric populations to establish whether the difference by sex of the present study is replicable. It is uncertain if the association between high ferritin and higher cardiometabolic risk reported in the Chilean cohort, commonly described in adults, would remain significant after adjustments for hepatic function markers.

Funding source

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

Conflicts of interest

No potential conflicts of interest relevant to this article exist.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.numecd.2018.11.008.

References

[1] Abril-Ulloa V, Flores-Mateo G, Sola-Alberich R, Manuel-y-Keenoy B, Arija V. Ferritin levels and risk of metabolic syndrome: meta-analysis of observational studies. BMC Public Health 2014;14:483.

[2] Bao W, Rong Y, Rong S, Liu L. Dietary iron intake, body iron stores, and the risk of type 2 diabetes: a systematic review and meta-analysis. BMC Med 2012;10:119.

[3] Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a meta-analysis of observational studies. Diabetes Metabol Res Rev 2014;30(5):372−94.

[4] Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51(8):2348−54.

[5] Fernandez-Real JM, McClain D, Manco M. Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. Diabetes Care 2015;38(11):2169−76.

[6] Lapice E, Masulli M, Vaccaro O. Iron deficiency and cardiovascular disease: an updated review of the evidence. Curr Atheroscler Rep 2013;15(10):358.

[7] Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. Pediatrics 2003;112(4):846−54.

[8] Burrows R, Correa-Burrows P, Reyes M, Blanco E, Albala C, Gahagan S. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. Publ Health Nutr 2016;19(3):486−93.

[9] Brage S, Wedderkopp N, Ekelund U, Franks PW, Wareham NJ, Andersen LB, et al. Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: the European Youth Heart Study (EYHS). Diabetes Care 2004;27(9):2141−8.

[10] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412−9.

[11] Bougle D, Brouard J. Iron in child obesity. Relationships with inflammation and metabolic risk factors. Nutrients 2013;5(6):2222−30.

[12] Lee HJ, Jang HB, Park JE, Park KH, Kang JH, Park SI, et al. Relationship between serum levels of body iron parameters and insulin resistance and metabolic syndrome in Korean children. Osong Publ Health Res Perspect 2014;5(4):204−10.

[13] Zhu YN, He BT, Jing J, Ma J, Li XH, Yang WH, et al. Hepcidin and iron metabolism associated with cardiometabolic risk factors in children: a case-control study. Nutrition, metabolism, and cardiovascular diseases. Nutr Metabol Cardiovasc Dis 2016;26(6):525−33.

[14] Jeon YJ, Jung IA, Kim SH, Cho WK, Jeong SH, Cho KS, et al. Serum ferritin level is higher in male adolescents with obesity: results from the Korean National Health and Nutrition Examination Survey 2010. Ann Pediatr Endocrinol Metabol 2013;18(3):141−7.

[15] Kim YE, Kim DH, Roh YK, Ju SY, Yoon YJ, Nam GE, et al. Relationship between serum ferritin levels and dyslipidemia in Korean adolescents. PLoS One 2016;11(4):e0153167.

[16] Yoon JH, Linton JA, Koh SB, Kang HT. Serum ferritin concentrations predict incidence of metabolic syndrome in rural Korean adults. Clin Chem Lab Med : CCLM / FESCC. 2012;50(11):2057−9.

[17] Vari IS, Balkau B, Kettaneh A, Andre P, Tichet J, Fumeron F, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007;30(7):1795−801.

[18] Kilani N, Vollenweider P, Waeber G, Marques-Vidal P. Iron metabolism and incidence of metabolic syndrome. Nutr Metabol Cardiovasc Dis : Nutr Metabol Cardiovasc Dis 2015.

[19] Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27(10):2422−8.

[20] Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metab Clin Exp 2011;60(3):414−20.

[21] Shi Z, Hu X, Yuan B, Hu G, Pan X, Holmboe-Ottesen G. Coexistence of anaemia and the metabolic syndrome in adults in Jiangsu, China. Asia Pac J Clin Nutr 2008;17(3):505−13.

[22] Hamalainen P, Saltevo J, Kautiainen H, Mantyselka P, Vanhala M. Serum ferritin levels and the development of metabolic syndrome and its components: a 6.5-year follow-up study. Diabetol Metab Syndrome 2014;6(1):114.

[23] Aigner E, Hinz C, Steiner K, Rossmann B, Pfleger J, Hohla F, et al. Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. Eur J Clin Investig 2010;40(2):155−63.

[24] Podmore C, Meidtner K, Schulze M-B, Scott R-A, Ramond A, Butterworth A-S, et al. The association of multiple biomarkers of iron metabolism and type 2 diabetes: the EPIC-interact study. Diabetes Care 2016;39:572−81.

[25] Zhao L, Zhang X, Shen Y, Fang X, Wang Y, Wang F. Obesity and iron deficiency: a quantitative meta-analysis. Obes Rev 2015;16:1081−93.

[26] Khan A, Khan WM, Ayub M, Humayun M, Haroon M. Ferritin is a marker of inflammation rather than iron deficiency in overweight and obese people. J Obes 2016;2016:1937320.

[27] Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011;55(2):453−8.

[28] Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5(1):27−42 [Review].

[29] Hutchinson C. A review of iron studies in overweight and obese children and adolescents: a double burden in the young? Eur J Nutr 2016;55(7):2179−97.

[30] Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360(9326):57−8.

[31] Anand SS, Yusuf S, Jacobs R, Davis AD, Yi Q, Gerstein H, et al. Risk factors, atherosclerosis, and cardiovascular disease among aboriginal people in Canada: the study of health assessment and risk evaluation in aboriginal peoples (SHARE-AP). Lancet 2001;358(9288):1147−53.

[32] McDonald S, Maguire G, Duarte N, Wang XL, Wendy HO. C-reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clin Sci 2004;106(2):121−8.

[33] Lapice E, Masulli M, Vaccaro O. Iron deficiency and cardiovascular disease: an updated review of the evidence. Curr Atheroscler Rep 2013;15(10):358.